Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Ovation Acquires Lundbeck's Antipsychotic Buronil

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Gaining FDA approval of melperone and two other recently acquired products – the anti-epileptics Sabril (vigabatrin) and Frisium (clobazam) – is a top priority for Ovation. The company has built a portfolio of 11 "under-performing" CNS products in less than two years.

You may also be interested in...



Questcor Acthar Gel Has Mid-’07 Action Date For Infantile Spasms, But Ovation To Seek Same Claim

Ovation plans to submit vigabatrin for the same indication in the coming weeks.

US FDA Expands Drug Development Tool Qualification Program With ISTAND Pilot

ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.

Table

View full table

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By